Vor Biopharma (VOR) Cash & Equivalents (2020 - 2026)

Vor Biopharma (VOR) has reported Cash & Equivalents for 7 consecutive years, with $169.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 239.43% year-over-year to $169.9 million; the TTM figure through Mar 2026 stood at $169.9 million (up 239.43% YoY), while the FY2025 annual figure was $396.5 million, up 383.82% from the prior year.
• Cash & Equivalents eased to $169.9 million in Q1 2026 per VOR's latest filing, from $396.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $396.5 million in Q4 2025 and bottomed at $31.4 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $96.8 million across 5 years, with a median of $60.8 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 65.71% — and 2025, when it jumped 383.82%.
• Vor Biopharma's Cash & Equivalents stood at $57.7 million in 2022, then slumped by 45.66% to $31.4 million in 2023, then soared by 161.32% to $81.9 million in 2024, then surged by 383.82% to $396.5 million in 2025, then sank by 57.16% to $169.9 million in 2026.
• Business Quant data shows VOR's Cash & Equivalents at $169.9 million in Q1 2026, $396.5 million in Q4 2025, and $160.5 million in Q3 2025.